U.S. health agency tells Grassley there is no EpiPen settlement yet

NEW YORK (Reuters) - Mylan NV has yet to reach a settlement with the U.S. Department of Justice over the classification in the Medicaid program of life-saving allergy treatment EpiPen, the acting head of a top U.S. government health regulatory agency told Senator Charles Grassley in a letter disclosed on Thursday.